[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_96":97},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","d0x5zby4driyqv0zmq17w48y4","revision",2,"title","Clinuvel Pharmaceuticals Ltd 6-K 文件发布","originalTitle","6-K - Clinuvel Pharmaceuticals Ltd (0001290877) (Filer)","summary","Clinuvel Pharmaceuticals Ltd 发布 6-K 文件，披露其在澳大利亚证券交易所提交的附录 3H 通知。文件内容涉及证券终止信息。公司管理层已签署该文件。","reason","source",{"_11":86,"_87":88,"_89":90,"_91":57,"_92":93,"_94":95},"links",{"_83":84,"_63":85},"publishedAt","2026-10-15T10:02:58.000Z","discoveredAt","2026-10-15T11:34:19.565Z","timelineAt","category","tip","tags",[81,82],"stockSymbols",[80],"score",21,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fS8NP-aMzGzo",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","019e72ab-2be9-4627-a8a5-3faad12d15af","Clinuvel 6-K 文件发布",{"_72":73,"_15":74},"zh","

UNITED\nSTATES

SECURITIES\nAND EXCHANGE COMMISSION

Washington,\nD.C. 20549

FORM\n6-K

REPORT\nOF FOREIGN PRIVATE ISSUER

PURSUANT\nTO RULE 13a-16 OR 15d-16

UNDER\nTHE SECURITIES EXCHANGE ACT OF 1934

For\nthe month of October 2026

Commission\nFile Number: 001-43353

CLINUVEL\nPHARMACEUTICALS LIMITED

Level\n22, 535 Bourke Street

Melbourne,\nVIC 3000

Australia

(Address\nof principal executive office)

Indicate\nby check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form\n20-F ☒ Form 40-F ☐

INFORMATION\nCONTAINED IN THIS FORM 6-K REPORT

On\nOctober 15, 2026, Clinuvel Pharmaceuticals Limited filed the following documents with the Australian Securities Exchange are furnished\nto this Form 6-K as Exhibit 99.1.

Exhibits

\n \n \n \n \n \n \n \n \n \n \n \n \n

Exhibit\n No.		Description

99.1		Appendix 3H - Notification of cessation of securities

SIGNATURES

Pursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned, thereunto duly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	CLINUVEL PHARMACEUTICALS LIMITED

Date: October 15, 2026	By:	/s/ Philippe\n Wolgen
	Name:	Philippe Wolgen
	Title:	Managing Director and Chief Executive Officer

","zhKind","complete","CUVL","政策与监管","退市","aihot","/items/d0x5zby4driyqv0zmq17w48y4","https://www.sec.gov/Archives/edgar/data/1290877/000149315226047083/0001493152-26-047083-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792281600&sig=7e2c0b2887bde829","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792281600&sig=4a4e737d69fc85ba 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792281600&sig=f06d97a3bb025478 96w","changelogVersion","2026-10-01T08:00"]